Active substance
Urofollitropin
- SFDA 6
- US FDA 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FOSTIMON HP 150 IU VIAL IM(WOMEN URIN) | 150 IU | Powder and solvent for solution for injection · Intramuscular use | 1 Vial | SAR 138.35 | Generic · Prescription | IBSA INSTITUTE BIOCHIMIQUE S.A | Valid |
| FOSTIMON HP 75 IU VIAL (IM) USE | 75 IU | Powder and solvent for solution for injection · Intramuscular use | 1 Vial | SAR 74.10 | Generic · Prescription | IBSA INSTITUTE BIOCHIMIQUE S.A | Valid |
| Fostimon 225 I.U | 225 IU | Powder and solvent for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 202.50 | Biological · Prescription | IBSA Istitut Biochimique SA | Valid |
| Fostimon 300 I.U | 300 IU | Powder and solvent for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 264.65 | Biological · Prescription | IBSA INSTITUTE BIOCHIMIQUE S.A | Valid |
| BRAVELLE 75IU POWDER FOR SOLU. FOR INJ | 75 IU | Powder and solvent for solution for injection · Intramuscular use | 5 Vial | SAR 251.60 | Generic · Prescription | FERRING | Withdrawn by MAH · Not Marketed |
| METRODIN HP 75 IU-AMPOULE | 75 IU | Injection · Intramuscular use | 1 Ampoule | SAR 72.50 | Generic · Prescription | SERONO | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| BRAVELLE | 0.9% | injectable · subcutaneous | FERRING | Prescription | 19 Dec 2002 |
| METRODIN | 75 IU/AMP; 150 IU/AMP | injectable · intramuscular | SERONO | Discontinued | 18 Sep 1986 |
| FERTINEX | 150 IU/AMP; 75 IU/AMP | injectable · subcutaneous | SERONO | Discontinued | 18 Sep 1986 |
| BRAVELLE | 75 IU/VIAL | injectable · intramuscular, subcutaneous | FERRING | Discontinued | 6 May 2002 |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.